Skip to content
thestock.space

Samsrita Labs (BSE: SAMSRITA) is loss-making over the last 12 months, losing ₹8.07 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹11.87, 53% below its 52-week high. Sales fell 5.7% a year over 3 years. Debt is 0.14× equity. It is a small-cap company with a market cap of ₹27 Cr, ranked 16th of 18 Diagnostics & Research companies by market cap; the shares fell 47% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹12.00
Day high
₹12.00
Day low
₹10.50
Prev. close
₹11.20
Volume
6K

Health check

6 to check
  • ReturnsBehind

    −46.8% over a year, better than 0 of 7 peers.

  • Price tagLoss-making

    Earnings were negative over the last 12 months.

  • GrowthShrinking

    Sales −5.7% a year over 3 years.

  • ProfitabilityNegative

    ROCE -6.5% vs peer median 19.1%.

  • Balance sheetStretched

    Debt 0.14× equity, Piotroski 2 of 9.

  • Red flags3 to check

    Loss-making over the last twelve months.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Small cap

₹27 Cr, #16 of 18 in its industry by size.

Defensive

Beta 0.29 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹0 Cr · profit ₹−8 Cr
Market cap
₹27 Cr
Small cap
P/E
n/a
Industry 52.8
Price to book
2.30
Peers 11.99
Dividend yield
0.00%
ROE
−68.8%
Peers 17.7%
ROCE
−6.5%
Peers 19.1%
Debt to equity
0.14
Debt ₹1.66 Cr
EPS (TTM)
−₹3.43
OPM (TTM)
−48285.0%
Net margin 0.0%
Sales growth
n/a
Year-ago quarter not reported
Profit growth
n/a
Year-ago quarter not reported
Price to sales
1489.21
EV/EBITDA −3.1

Strengths and risks

Risks to check

  • Loss-making over the last twelve months.
  • Return on equity is low at −68.8%.
  • 53% below its 52-week high.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Samsrita Labs

Samsrita Labs Limited operates as a biopharmaceutical company in India. It offers DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and prenatal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype, and…

Headquarters
Hyderabad
Employees
5
Sector
Healthcare
ISIN
INE579N01018
Website
drhlsl.com

Price range

52 weeks

₹10.15₹25.27

Today

₹10.50₹12.00
Avg volume (3M)
8.6K
1-year return
minus 46.8%
From 52-week high
minus 53.0%

Peers · Diagnostics & Research

Compare with peersScreen the whole industry
Company
SAILIFESai Life Sciences1,785.10plus 11.95%37,929101.515.2218.1%15.1%28.7%21.3%226.8%0.00%plus 72.7%
LALPATHLABDr. Lal Path Labs1,970.00plus 0.16%32,94156.511.9925.7%22.6%30.2%11.1%28.3%1.02%plus 24.7%
SYNGENESyngene International417.30plus 0.77%16,77290.33.468.3%3.9%25.7%5.4%−12.0%0.30%minus 36.0%
VIJAYAVijaya Diagnostic Centre1,468.60plus 2.15%15,12674.414.2919.1%21.2%43.1%21.0%26.9%0.14%plus 40.2%
METROPOLISMetropolis Healthcare568.75minus 0.39%11,80352.87.1715.7%14.6%21.7%12.7%10.0%0.35%plus 12.5%
THYROCAREThyrocare Technologies493.10plus 0.68%7,84855.014.7533.8%26.4%32.2%16.7%36.2%1.89%plus 8.3%
VIMTALABSVimta Labs496.45minus 2.14%2,21927.94.5221.0%17.7%34.7%8.9%17.2%0.40%minus 23.3%
SAMSRITASamsrita Labs11.87plus 5.98%27–2.30−6.5%−68.8%−48285.0%−5.7%–0.00%minus 46.8%
Median of 7 peers–0.68%15,12656.511.9919.1%17.7%30.2%12.7%26.9%0.35%12.5%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrMar 25Dec 25Mar 26Jun 26
––0–
––0.2–
−0.1−3.4−0.1−0.3
––−828.2%–
−0000
0000
−0.1−3.4−0.1−0.3
−0.1−2.9−0.5−0.2
–-1.29-0.06-0.08

Jun 25, Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−5.7%
ROE
−68.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
0––0
0.3––0.8
−0.2−0.2−0.3−0.8
−1152.5%––−4258.7%
0.3−0−00
0000
−0.7––−7.9
−0.7−0.2−0.3−8.7
−0.7−0.3−0.3−8.2
-0.48-0.18-0.19-3.99

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
14.814.814.822.7
−2.3−2.6−2.8−11
2.12.22.41.7
11.11.21
15.615.615.614.4
0000
6.96.9–9.8
0001.6
8.78.715.62.9
15.615.615.614.4

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
0.7−0.1−0.2−4.3
–––3.3
0.70.10.22.6
1.3−0−01.6
0.7−0.1−0.2−4.3

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you